Milestone Pharmaceuticals Inc.
CARDAMYST
paroxysmal supraventricular tachycardia (PSVT)
Resolved
207days ago
Approval decision · Dec 12, 2025
What's at stake
A final FDA approval decision on CARDAMYST for paroxysmal supraventricular tachycardia (PSVT) is expected Dec 12, 2025.
Primary source
· SEC 8-K
verified 15h ago
“CARDAMYST nasal spray was approved by the FDA on December 12, 2025.”